Advances in medicine and biology [[electronic resource] ] . Volume 6 / / Leon V. Berhardt, editor

• Record Nr.: UNINA9910778822303321
• Pubbl/distr/stampa: New York, : Nova Biomedical Books, c2010
• ISBN: 1-61728-045-3
• Descrizione fisica: 1 online resource (296 p.)
• Collana: Advances in Medicine and Biology ; ; v.6
• Altri autori (Persone): BerhardtLeon V
• Disciplina: 616
• Soggetti: Medicine; Biology
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: ""ADVANCES IN MEDICINE AND BIOLOGY VOLUME 6""; ""CONTENTS""; ""PREFACE""; ""ZINC-BASED BIOMATERIALS""; ""BIOLOGICAL ASPECTS OF ZINC""; ""ZINC BIOMATERIALS""; ""ZINC OXYCHLORIDE CEMENTS""; ""ZINC OXIDE EUGENOL CEMENTS""; ""ZINC PHOSPHATE CEMENTS""; ""ZINC POLYCARBOXYLATE CEMENTS""; ""GLASS POLY(ALKENOATE) CEMENTS""; ""GLASSES USED IN GPCS""; ""ACID COMPONENTS USED IN GPCS""; ""THE ROLE OF ADDITIVES TO GPCS""; ""MECHANICAL PROPERTIES OF GPCS""; ""BIOLOGICAL AND ION RELEASE PROPERTIES OF GPCS""; ""ALUMINIUM FREE GPCS""; ""STRUCTURE AND REACTIVITY OF ALUMINIUM FREE IONOMERGLASSES""; ""STRENGTH OF ALUMINIUM-FREE GPCS""""OPTIMISATION OF RHEOLOGICAL PROPERTIES OF ZN-GPCS""; ""IN VITRO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""IN VIVO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""OTHER ASPECTS OF ALUMINIUM-FREE GPCS""; ""APPLICATIONS FOR ALUMINIUM-FREE GPCS""; ""FUTURE PERSPECTIVES OF ALUMINIUM-FREE GPCS""; ""REFERENCES""; ""THE EFFECTS OF DRUGS ON VERBAL FLUENCY:MECHANISMS OF DRUG RELATED FLUENCY INAPHASIA""; ""ABSTRACT""; ""INTRODUCTION""; ""NEUROANATOMY OF SPEECH AND LANGUAGE""; ""NEUROCHEMICAL BASES OF SPEECH AND LANGUAGE""; ""The Primary Neurotransmitters""; ""Glutamate, γ-Aminobutyric Acid and Glycine""""Neuromodulators and Hormones""; ""Catecholamines""; ""Acetylcholine""; ""Serotonin""; ""DEFINITION OF FLUENCY""; ""NEUROPHARMACOLOGY OF VERBAL ; FLUENCY, SPEECH ANDLANGUAGE""; ""Agents which Increase Cerebral Perfusion""; ""Dopaminergic Agents""; ""Amphetamines""; ""Serotonin""; ""Cholinergic Drugs""; ""Piracetam""; ""Zolpidem""; ""Amantadine""; ""Antiepileptic Agents""; ""Drugs which have Speech and Language Side Effects""; ""CLINICAL CASE""; ""CONCLUSION""; ""REFERENCES""; ""PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE""; ""ABSTRACT""; ""1. CLINICAL FEATURES OF PSORIASIS""""2. TREATMENT OPTIONS FOR PSORIASIS""; ""3. PATHOGENESIS OF PSORIASIS""; ""4. SYSTEMIC MANIFESTATIONS OF INFLAMMATORYDISORDERS""; ""5. CLINICAL LINK BETWEEN PSORIASIS ANDATHEROSCLEROSIS""; ""6. OPHTHALMIC AND RENAL MANIFESTATIONS OFPSORIASIS""; ""7. SIMILARITIES BETWEEN MOLECULAR MECHANISMS OFPSORIASIS AND OTHER INFLAMMATORY DISORDERS""; ""8. CAN TREATMENT OF PSORIASIS ALSO IMPROVE ITSSYSTEMIC MANIFESTATION?""; ""9. DELINEATING PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE: ""5 YEAR VIEW""""; ""REFERENCES""; ""REPACKAGING OF ANTI-GLAUCOMAMEDICINES:NEW THERAPEUTIC VISTAS""""ABSTRACT""; ""INTRODUCTION""; ""CHOLINERGIC AGENTS""; ""Pilocarpine""; ""NON-SELECTIVE ADRENERGIC AGONISTS""; ""CARBONIC ANHYDRASE INHIBITORS""; ""Acetazolamide""; ""Dorzolamide and Brinzolamide""; ""α2-ADRENERGIC AGONIST""; ""BETA-BLOCKING AGENTS""; ""Timolol""; ""Betaxolol""; ""Levobunolol""; ""Carteolol""; ""PROSTAGLANDIN ANALOGS""; ""Unoprostone Isopropylate""; ""Latanoprost""; ""COMBIMATION""; ""CONCLUSION""; ""REFERENCES""; ""THE UTILIZATION OF TECHNOLOGY IN THETREATMENT OF OBSESSIVE COMPULSIVEDISORDER""; ""ABSTRACT""; ""INTRODUCTION""